Loading stock data…
$0.98-0.01 (-1.07%)
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
ABVC BioPharma, Inc. in the Healthcare sector is trading at $0.98 with a market capitalization of $26M. The stock is currently near its 52-week low of $0.71, remaining 26.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↑ | -$795,950 | $0 | $0 |
| Gross Profit | $0 | $0↑ | -$795,950 | $0 | $0 |
| Operating Income | -$779,526↑ | -$1.57M↑ | -$2.99M↓ | -$1.96M↑ | -$2.29M |
| Net Income | -$736,934↑ | -$1.56M↑ | -$3.56M↓ | -$2.04M↑ | -$2.26M |
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therap...